Home | Contact Us  |  BMCNET  |  Hotline 1565
Patients & Visitors
Patients & Visitors
Useful Information
Find a Doctor
Online Request
Lab Results
International Patients
Admission, Insurance & Billing
Patients Feedback Form
Patient Satisfaction & Testimonials
Patients Rights & Responsibilities
Community Affairs
Clinical Research
Organ Donation
Patient Centered Approaches
Patient Education
Pre-Admission Unit Instructions

Clinical Research
As part of our commitment to advances and innovation in medicine, Bellevue University Medical Center participates in the conduct of research in various fields, all of which are of the highest caliber, many of which are multi-centered and international. Below is a list of the clinical research trials ongoing at Bellevue University Medical Center:


Uterine Factor Infertility (UFI) is a condition where a woman cannot carry a pregnancy because she was born without a uterus, or has a dysfunctional uterus (for e.g. from cancer or other disease). At least 100,000 women are estimated to be affected in MENAT by this type of infertility which is the only one lacking a treatment today.

At the Sahlengrenska Academy, the University of Gothenburg and the Sahlgrenska University Hospital in Sweden, a research project has been ongoing since 1999 which aims to provide women with the possibility of having biological children with the aid of a transplanted uterus. The Swedish research team accomplished its first birth in September 2014 and has performed a total of nine uterus transplants that have resulted in five pregnancies and four live births.

Bellevue Medical Center, renowned for its high quality standards, has been chosen by the Swedish team for an exclusive partnership in the Middle East/North Africa & Turkey Region, to perform the pioneer uterus transplant among the first worldwide centers.

Click HERE for more info.


A randomized double-blind, placebo-controlled study of LEEOll in combination with letrozole for the treatment of postmenopausal women with hormone receptor positive, HER2 negative, advanced breast cancer who received no prior therapy for advanced disease.


A phase III randomized , double blind, placebo controlled study of LEE011 or placebo in combination with tamoxifen and goserelin or a non-steroidal aromatase inhibitor (NSAI) and goserelin for the treatment of premenopausal women with hormone receptor positive, HER 2 negative, advanced breast cancer.
Click here for more details.

For more information, please ask your physician or call Ext. 7600.